Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity - PR Newswire
Peptide Research News surfaces this story from PR Newswire. Read the complete article at the original source:
Read the full article at PR Newswire →